On August 4, Hinge Health (NASDAQ:HNGE) delivered a quarter that beat its own guidance on nearly every line, then turned around and used the extra cash to buy its way into a brand new category. Revenue grew 53% year-over-year, margins expanded by roughly 1,000 basis points, and the company still found $105 million to acquire a gastrointestinal care startup. That is the kind of quarter that raises a different question: can a company already growing this fast keep adding new conditions to its platform without stretching itself thin?
Bull Case: A Platform Built To Multiply
Second-quarter revenue came in at $213 million, up 53% from $139 million a year earlier and well above the company’s guidance range of $200 million to $202 million. Last-12-month calculated billings reached $862 million, up 52% from $568 million a year ago, and CFO James Budge said the beat came almost entirely from stronger yield rather than more lives or a higher price per member. Gross margin hit 87%, up more than 400 basis points from 83% in the prior-year quarter, while operating income more than doubled to $62 million and operating margin expanded to 29% from 19%. Free cash flow tripled to $100 million, a 47% margin, funding both the Cylinder Health acquisition and a fresh $300 million buyback authorization approved by the board.
CEO Daniel Perez framed the Cylinder deal, announced this quarter for $105 million in cash, as the company’s entry into gastrointestinal care, a condition he said affects one in four US adults and drives $135 billion in annual medical spending. Cylinder brings nearly 100 clients, 2 million covered lives, and partnerships with two of the three largest pharmacy benefit managers. Migraine, the company’s other new product launched last quarter, has already signed up more than 450 clients covering over 5 million lives, and President Jim Pursley said more than 10 health plans have turned the program on for clients under existing contracts.
Bear Case: The Parts Still Unproven
Not everything in this quarter is finished business. Cylinder Health is expected to close later in the quarter and contribute only $7 million to $8 million in revenue over the remaining four months of 2026, with Perez himself calling GI a “modest contribution” this year and pointing to a broader rollout in 2027. That means the near-term payoff of a $105 million acquisition rests almost entirely on integration work that Perez said is still underway.
Part of this quarter’s gross margin gain came from a one-time tariff refund worth about 100 basis points, a boost that will not repeat. Diluted share count is also set to climb, from 83.4 million in the quarter to an expected 85 million to 87 million by year-end, largely from remaining preferred shares converting to common, which dilutes the per-share benefit of all this growth. And several of the company’s biggest wins this quarter, including a nearly 300,000-life enterprise account and a national health plan’s SMB business, came from directly displacing an existing competitor, a reminder that Hinge Health is fighting for share in a market other vendors are already serving.
Market Sentiment
Hedge fund ownership slipped from 48 funds to 43 in the most recent quarter, a modest pullback rather than a rush for the exits. Short interest, by contrast, sits at 9.67% of float, a meaningfully higher level that points to a real bear camp betting against the stock. As of August 12, the forward P/E of 40.32 shows investors are still paying a steep premium for growth, leaving little room for a miss.
Two Growth Stories Racing Each Other
Hinge Health’s core MSK business is throwing off enough cash to fund acquisitions and buybacks at the same time, and management raised full-year revenue guidance to $856 million to $860 million on the strength of durable yield gains. The bull case rests on that cash engine successfully extending into migraine and GI without losing focus on the business that built it.
While we acknowledge the risk and potential of HNGE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HNGE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
